Adenovirus/PNP
- Generic Name
- Adenovirus/PNP
- Drug Type
- Biotech
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Phase 1
Completed
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03754933
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Winship Cancer Institute - Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath